Acquiring Company
VistaGen
Acquired Company
Pherin
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaTherapeuticsPharmaceuticalDescription
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions (Pherin). Vistagen now owns all intellectual property rights to its two most advanced drug candidates, PH94B, currently in Phase 3 development for social anxiety disorder (SAD) and Phase 2 development for adjustment disorder with anxiety (AjDA), and PH10, in clinical development for major depressive disorder (MDD), as well as three additional drug candidates in earlier stages of development: PH15 for cognition improvement; PH80 for migraine and hot flashes; and PH284 for appetite-related disorders. Vistagen’s acquisition of Pherin eliminates all future royalty payment obligations related to its five pherine nasal spray drug candidates.
Quick answer
VistaGen is acquiring Pherin, announced February 2, 2023. VistaGen is based in South San Francisco, California, United States.
- How much did VistaGen pay for Pherin?
- The deal value was not disclosed.
- What does VistaGen do?
- Vistagen is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, CA, developing and commercializing a new class of intranasal product candidates called pherines.
- Where are VistaGen and Pherin based?
- VistaGen is based in South San Francisco, California, United States.
- Who are the decision-makers at VistaGen?
- Fundz holds 1 contact at VistaGen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Sumitovant Biopharma Completes Acquisition Of Myovant Sciences (March 10, 2023)
- Vistagen To Acquire Pherin Pharmaceuticals (December 21, 2022)
- Merck Completes Tender Offer To Acquire Imago Biosciences, Inc. (January 11, 2023)
- Rhythm Pharmaceuticals Announces Acquisition Of Xinvento B.V. And Portfolio Of Investigational Therapeutics (February 27, 2023)
- Kymanox Acquires Eu Based Anteris Medical And Anteris Helvetia (February 2, 2023)
- Lg Chem Completes Acquisition Of Aveo Oncology (January 19, 2023)
Who to call at VistaGen, and when
When VistaGen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day VistaGen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at VistaGen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at VistaGen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment VistaGen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Pherin?
Pherin was acquired by VistaGen, based in South San Francisco. The deal was reported on February 2, 2023. Vistagen is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, CA, developing and commercializing a new class of intranasal product candidates called pherines. VistaGen is publicly traded (VTGN) and operates in Biotechnology.
When did VistaGen acquire Pherin?
VistaGen's acquisition of Pherin was reported on February 2, 2023. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Pherin do?
Pherin Pharmaceuticals is a privately held company focused on the discovery and development of pherines for acute, intermittent, and long-term treatment of a broad range of human diseases and disorders. It is privately held, operating in Therapeutics.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.